InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,478.49
(
0.95%
)
US TECH 100
18,681.20
(
0.79%
)
Dow Jones
40,340.55
(
1.22%
)
Brent Oil
81.28
(
0.67%
)
Bitcoin
64,870.51
(
-0.77%
)
Post# of 252676
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: None

Thursday, 11/29/2012 4:07:35 PM

Thursday, November 29, 2012 4:07:35 PM

Post# of 252676
EXEL approval:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up